Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;33(6):1304-8.
doi: 10.2337/dc09-1791. Epub 2010 Mar 18.

Long-term metformin use is associated with decreased risk of breast cancer

Michael Bodmer  1 , Christian Meier, Stephan Krähenbühl, Susan S Jick, Christoph R Meier
Affiliations

Long-term metformin use is associated with decreased risk of breast cancer

Michael Bodmer et al. Diabetes Care. 2010 Jun.

Abstract

Objective: To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women.

Research design and methods: Using the U.K.-based General Practice Research Database, we conducted a nested case-control analysis among 22,621 female users of oral antidiabetes drugs with type 2 diabetes. We evaluated whether they had an altered risk of breast cancer in relation to use of various types of oral hypoglycemic agents. Case and control patients with a recorded diagnosis of type 2 diabetes were matched on age, calendar time, and general practice, and the multivariate conditional logistic regression analyses were further adjusted for use of oral antidiabetes drugs, insulin, estrogens, smoking BMI, diabetes duration, and HbA1c (A1C).

Results: We identified 305 case patients with a recorded incident diagnosis of breast cancer. The mean +/- SD age was 67.5 +/- 10.5 years at the time of the cancer diagnosis. Long-term use of >or=40 prescriptions (>5 years) of metformin, based on 17 exposed case patients and 120 exposed control patients, was associated with an adjusted odds ratio of 0.44 (95% CI 0.24-0.82) for developing breast cancer compared with no use of metformin. Neither short-term metformin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk for breast cancer.

Conclusions: A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis.

PubMed Disclaimer

Comment in

References

    1. Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007;86:s823–s835 - PubMed
    1. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23–37 - PubMed
    1. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE: Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 2006;98:303–309 - PubMed
    1. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42–51 - PubMed
    1. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE: The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008;109:389–395 - PubMed

Publication types